{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:17:49Z","timestamp":1784207869066,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFE0207300"],"award-info":[{"award-number":["2018YFE0207300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["M23008"],"award-info":[{"award-number":["M23008"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28405","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T13:05:25Z","timestamp":1710853525000},"page":"e28405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-3306","authenticated-orcid":false,"given":"Haolong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e28405_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jiph.2022.11.024","article-title":"Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies","volume":"16","author":"Dhama","year":"2023","journal-title":"Journal of infection and public health"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28405_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28405_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11102681","article-title":"COVID-19 and autoimmune liver diseases","volume":"11","author":"Floreani","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e28405_bib4","article-title":"Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes","author":"Ampuero","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28405_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28405_bib6","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1093\/cid\/ciac404","article-title":"Humoral and T-cell immune response after 3 doses of Messenger RNA severe acute respiratory syndrome coronavirus 2 vaccines in fragile patients: the Italian VAX4FRAIL study","volume":"76","author":"Corradini","year":"2023","journal-title":"Clin. Infect. Dis. : an official publication of the Infectious Diseases Society of America"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28405_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1042\/CS20181123","article-title":"Immunological abnormalities in patients with primary biliary cholangitis","volume":"133","author":"Ma","year":"2019","journal-title":"Clinical science (London, England : 1979)"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28405_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00299-20","article-title":"Critical determinants of cytokine storm and type I interferon response in COVID-19 pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin. Microbiol. Rev."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28405_bib9","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3748\/wjg.v29.i12.1838","article-title":"Autoimmune liver diseases and SARS-CoV-2","volume":"29","author":"Sgamato","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"44","key":"10.1016\/j.heliyon.2024.e28405_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001888","article-title":"The distribution and the fibrotic role of elevated inflammatory Th17 cells in patients with primary biliary cirrhosis","volume":"94","author":"Shi","year":"2015","journal-title":"Medicine"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e28405_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21037\/atm.2019.07.100","article-title":"The expression and clinical significance of serum IL-17 in patients with primary biliary cirrhosis","volume":"7","author":"Sun","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e28405_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155291","article-title":"Characteristics of serum chemokine profile in primary biliary cholangitis","volume":"136","author":"Mu","year":"2020","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28405_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ueg2.12218","article-title":"SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease","volume":"10","author":"Duengelhoef","year":"2022","journal-title":"United European gastroenterology journal"},{"issue":"10282","key":"10.1016\/j.heliyon.2024.e28405_bib14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28405_bib15","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/1753-0407.13448","article-title":"Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization","volume":"15","author":"Li","year":"2023","journal-title":"J. Diabetes"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28405_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28428","article-title":"Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV","volume":"95","author":"Zhan","year":"2023","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28405_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac261","article-title":"Hiplot: a comprehensive and easy-to-use web service for boosting publication-ready biomedical data visualization","volume":"23","author":"Li","year":"2022","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.heliyon.2024.e28405_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1107866","article-title":"Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: a prospective, multicenter, longitudinal study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28405_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac088","article-title":"Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population","volume":"51","author":"Okyar Ba\u015f","year":"2022","journal-title":"Age Ageing"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28405_bib20","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11684-021-0914-x","article-title":"Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults","volume":"16","author":"Zhang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.heliyon.2024.e28405_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027924","article-title":"The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: an observational study","volume":"13","author":"Ou","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28405_bib22","first-page":"257","article-title":"Challenges to diagnosis and management of autoimmune liver diseases","volume":"23","author":"Wang","year":"2018","journal-title":"Chin. J. Gastroenterol."},{"key":"10.1016\/j.heliyon.2024.e28405_bib23","article-title":"Immunogenicity of inactivated SARS-CoV-2 vaccines in patients with rheumatoid arthritis: a case series","volume":"10","author":"Zhao","year":"2022","journal-title":"Front. Public Health"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28405_bib24","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s10067-022-06134-x","article-title":"Inactivated SARS-CoV-2 vaccine in primary Sj\u00f6gren's syndrome: humoral response, safety, and effects on disease activity","volume":"41","author":"Pasoto","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28405_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10060853","article-title":"Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored\/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: a prospective cohort study","volume":"10","author":"Assawasaksakul","year":"2022","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28405_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.12.015","article-title":"COVID-19-neutralizing antibodies predict disease severity and survival","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28405_bib27","article-title":"Heterologous prime-boost strategies for COVID-19 vaccines","volume":"29","author":"Sapkota","year":"2022","journal-title":"J. Trav. Med."},{"issue":"6561","key":"10.1016\/j.heliyon.2024.e28405_bib28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.abj4176","article-title":"Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants","volume":"373","author":"Pegu","year":"2021","journal-title":"Science (New York, NY)"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28405_bib29","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e28405_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.1067342","article-title":"Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: a cross-sectional observational study","volume":"10","author":"Guo","year":"2022","journal-title":"Front. Public Health"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28405_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.virs.2023.07.005","article-title":"Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases","volume":"38","author":"Liu","year":"2023","journal-title":"Virol. Sin."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28405_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nri3152","article-title":"Expanding roles for CD4\u207a T cells in immunity to viruses","volume":"12","author":"Swain","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28405_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7150\/ijms.79116","article-title":"Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages","volume":"20","author":"Wang","year":"2023","journal-title":"Int. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e28405_bib34","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e28405_bib35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.virs.2022.11.007","article-title":"The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages","volume":"37","author":"Xiang","year":"2022","journal-title":"Virol. Sin."},{"issue":"6583","key":"10.1016\/j.heliyon.2024.e28405_bib36","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1126\/science.abn8652","article-title":"Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement","volume":"375","author":"McCallum","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"78","key":"10.1016\/j.heliyon.2024.e28405_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade9888","article-title":"Exposure to BA.4\/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4\/5 in vaccine-experienced humans and mice","volume":"7","author":"Muik","year":"2022","journal-title":"Science immunology"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28405_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2022.07.002","article-title":"SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns","volume":"30","author":"Gruell","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"14","key":"10.1016\/j.heliyon.2024.e28405_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"issue":"6591","key":"10.1016\/j.heliyon.2024.e28405_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8897","article-title":"Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529","volume":"376","author":"Zhou","year":"2022","journal-title":"Science (New York, NY)"},{"issue":"7857","key":"10.1016\/j.heliyon.2024.e28405_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28405_bib42","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"issue":"7950","key":"10.1016\/j.heliyon.2024.e28405_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","article-title":"FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2","volume":"615","author":"Brevini","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28405_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/joim.13630","article-title":"Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis","volume":"293","author":"John","year":"2023","journal-title":"Journal of internal medicine"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:56:53Z","timestamp":1784206613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024044360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024044360"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28405","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28405"}}